In vitro studies with Sch 21420 and Sch 22591

activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci

C. C. Sanders, W. E. Sanders, Richard V. Goering

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In vitro tests were performed with Sch 21420 and Sch 22591 to determine their activity in comparison to six other aminoglycosides against 343 clinical isolates, and whether synergy with penicillin G could be demonstrated with enterococci. In broth dilution tests, Sch 22591 was more active than the seven other aminoglycosides against Staphylococcus aureus, Enterobacteriaceae, and most nonfermenting gram-negative bacilli. Sch 22591 was as active as tobramycin against Pseudomonas aeruginosa. The activity of Sch 21420 was comparable to gentamicin, sisomicin, netilmicin, and tobramycin but greater than amikacin or kanamycin against S. aureus and most genera of Enterobacteriaceae. Sch 21420, amikacin, and kanamycin were more active than the other five aminoglycosides against Proteus rettgeri and Providencia stuartii, but less active than the other five aminoglycosides against Neisseria gonorrhoeae, enterococci, most nonfermenting gram-negative bacilli, Proteus mirabilis, and Proteus morganii. Studies on the bacterial activity of Sch 22591 with penicillin indicated a synergistic interaction against enterococci, including strains highly resistant to streptomycin and kanamycin. This could be demonstrated with combinations containing 3.0 to 6.0 μg of Sch 22591 per ml and was comparable to that observed with penicillin/gentamicin. Penicillin plus Sch 21420 (25 μg/ml) also demonstrated synergy against enterococci, including strains highly resistant to streptomycin. However, synergy did not occur against strains highly resistant to kanamycin. These latter results were similar to those obtained in tests with penicillin/kanamycin.

Original languageEnglish
Pages (from-to)178-184
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume14
Issue number2
StatePublished - 1978

Fingerprint

Kanamycin
Enterococcus
Aminoglycosides
Penicillins
Proteus
Tobramycin
Amikacin
Streptomycin
Enterobacteriaceae
Gentamicins
Bacillus
Staphylococcus aureus
Sisomicin
Providencia
Netilmicin
Proteus mirabilis
Penicillin G
Neisseria gonorrhoeae
Pseudomonas aeruginosa
isepamicin

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

@article{618fa02b32174bcc8fb6fb4f3cb90592,
title = "In vitro studies with Sch 21420 and Sch 22591: activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci",
abstract = "In vitro tests were performed with Sch 21420 and Sch 22591 to determine their activity in comparison to six other aminoglycosides against 343 clinical isolates, and whether synergy with penicillin G could be demonstrated with enterococci. In broth dilution tests, Sch 22591 was more active than the seven other aminoglycosides against Staphylococcus aureus, Enterobacteriaceae, and most nonfermenting gram-negative bacilli. Sch 22591 was as active as tobramycin against Pseudomonas aeruginosa. The activity of Sch 21420 was comparable to gentamicin, sisomicin, netilmicin, and tobramycin but greater than amikacin or kanamycin against S. aureus and most genera of Enterobacteriaceae. Sch 21420, amikacin, and kanamycin were more active than the other five aminoglycosides against Proteus rettgeri and Providencia stuartii, but less active than the other five aminoglycosides against Neisseria gonorrhoeae, enterococci, most nonfermenting gram-negative bacilli, Proteus mirabilis, and Proteus morganii. Studies on the bacterial activity of Sch 22591 with penicillin indicated a synergistic interaction against enterococci, including strains highly resistant to streptomycin and kanamycin. This could be demonstrated with combinations containing 3.0 to 6.0 μg of Sch 22591 per ml and was comparable to that observed with penicillin/gentamicin. Penicillin plus Sch 21420 (25 μg/ml) also demonstrated synergy against enterococci, including strains highly resistant to streptomycin. However, synergy did not occur against strains highly resistant to kanamycin. These latter results were similar to those obtained in tests with penicillin/kanamycin.",
author = "Sanders, {C. C.} and Sanders, {W. E.} and Goering, {Richard V.}",
year = "1978",
language = "English",
volume = "14",
pages = "178--184",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - In vitro studies with Sch 21420 and Sch 22591

T2 - activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci

AU - Sanders, C. C.

AU - Sanders, W. E.

AU - Goering, Richard V.

PY - 1978

Y1 - 1978

N2 - In vitro tests were performed with Sch 21420 and Sch 22591 to determine their activity in comparison to six other aminoglycosides against 343 clinical isolates, and whether synergy with penicillin G could be demonstrated with enterococci. In broth dilution tests, Sch 22591 was more active than the seven other aminoglycosides against Staphylococcus aureus, Enterobacteriaceae, and most nonfermenting gram-negative bacilli. Sch 22591 was as active as tobramycin against Pseudomonas aeruginosa. The activity of Sch 21420 was comparable to gentamicin, sisomicin, netilmicin, and tobramycin but greater than amikacin or kanamycin against S. aureus and most genera of Enterobacteriaceae. Sch 21420, amikacin, and kanamycin were more active than the other five aminoglycosides against Proteus rettgeri and Providencia stuartii, but less active than the other five aminoglycosides against Neisseria gonorrhoeae, enterococci, most nonfermenting gram-negative bacilli, Proteus mirabilis, and Proteus morganii. Studies on the bacterial activity of Sch 22591 with penicillin indicated a synergistic interaction against enterococci, including strains highly resistant to streptomycin and kanamycin. This could be demonstrated with combinations containing 3.0 to 6.0 μg of Sch 22591 per ml and was comparable to that observed with penicillin/gentamicin. Penicillin plus Sch 21420 (25 μg/ml) also demonstrated synergy against enterococci, including strains highly resistant to streptomycin. However, synergy did not occur against strains highly resistant to kanamycin. These latter results were similar to those obtained in tests with penicillin/kanamycin.

AB - In vitro tests were performed with Sch 21420 and Sch 22591 to determine their activity in comparison to six other aminoglycosides against 343 clinical isolates, and whether synergy with penicillin G could be demonstrated with enterococci. In broth dilution tests, Sch 22591 was more active than the seven other aminoglycosides against Staphylococcus aureus, Enterobacteriaceae, and most nonfermenting gram-negative bacilli. Sch 22591 was as active as tobramycin against Pseudomonas aeruginosa. The activity of Sch 21420 was comparable to gentamicin, sisomicin, netilmicin, and tobramycin but greater than amikacin or kanamycin against S. aureus and most genera of Enterobacteriaceae. Sch 21420, amikacin, and kanamycin were more active than the other five aminoglycosides against Proteus rettgeri and Providencia stuartii, but less active than the other five aminoglycosides against Neisseria gonorrhoeae, enterococci, most nonfermenting gram-negative bacilli, Proteus mirabilis, and Proteus morganii. Studies on the bacterial activity of Sch 22591 with penicillin indicated a synergistic interaction against enterococci, including strains highly resistant to streptomycin and kanamycin. This could be demonstrated with combinations containing 3.0 to 6.0 μg of Sch 22591 per ml and was comparable to that observed with penicillin/gentamicin. Penicillin plus Sch 21420 (25 μg/ml) also demonstrated synergy against enterococci, including strains highly resistant to streptomycin. However, synergy did not occur against strains highly resistant to kanamycin. These latter results were similar to those obtained in tests with penicillin/kanamycin.

UR - http://www.scopus.com/inward/record.url?scp=0018138254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018138254&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 178

EP - 184

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -